Pregabalin - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for pregabalin and what is the scope of freedom to operate?
Pregabalin
is the generic ingredient in three branded drugs marketed by Upjohn, Acme Labs, Actavis Elizabeth, Adaptis, Alembic, Alkem Labs Ltd, Amneal Pharms Co, Apotex, Aurobindo Pharma, Cadila Pharms Ltd, Changzhou Pharm, Chartwell Rx, Cipla, Creekwood Pharms, Dr Reddys, Eskayef, Hetero Labs Ltd Iii, Invagen Pharms, Lupin Ltd, MSN, Norvium Bioscience, Prinston Inc, Rising, Sciegen Pharms Inc, Strides Pharma, Sun Pharm, Teva Pharms, Yiling, Zydus Pharms, Anda Repository, Alvogen, Epic Pharma Llc, and Rubicon, and is included in forty-eight NDAs. There are three patents protecting this compound and six Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Pregabalin has thirty-seven patent family members in thirty-three countries.
There are forty-one drug master file entries for pregabalin. Fifty-five suppliers are listed for this compound. There are eight tentative approvals for this compound.
Summary for pregabalin
International Patents: | 37 |
US Patents: | 3 |
Tradenames: | 3 |
Applicants: | 33 |
NDAs: | 48 |
Drug Master File Entries: | 41 |
Finished Product Suppliers / Packagers: | 55 |
Raw Ingredient (Bulk) Api Vendors: | 101 |
Clinical Trials: | 526 |
Patent Applications: | 5,788 |
Drug Prices: | Drug price trends for pregabalin |
Drug Sales Revenues: | Drug sales revenues for pregabalin |
What excipients (inactive ingredients) are in pregabalin? | pregabalin excipients list |
DailyMed Link: | pregabalin at DailyMed |
Recent Clinical Trials for pregabalin
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Jules Bordet Institute | Phase 2 |
University of Milan | Phase 2 |
KU Leuven | Phase 2 |
Generic filers with tentative approvals for PREGABALIN
Applicant | Application No. | Strength | Dosage Form |
⤷ Subscribe | ⤷ Subscribe | 300MG | CAPSULE;ORAL |
⤷ Subscribe | ⤷ Subscribe | 225MG | CAPSULE;ORAL |
⤷ Subscribe | ⤷ Subscribe | 200MG | CAPSULE;ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Medical Subject Heading (MeSH) Categories for pregabalin
Anatomical Therapeutic Chemical (ATC) Classes for pregabalin
Paragraph IV (Patent) Challenges for PREGABALIN
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
LYRICA CR | Extended-release Tablets | pregabalin | 82.5 mg and 165 mg | 209501 | 1 | 2018-02-02 |
LYRICA CR | Extended-release Tablets | pregabalin | 330 mg | 209501 | 1 | 2018-01-29 |
LYRICA | Oral Solution | pregabalin | 20 mg/mL | 022488 | 1 | 2010-05-19 |
LYRICA | Capsules | pregabalin | 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg | 021446 | 8 | 2008-12-30 |
US Patents and Regulatory Information for pregabalin
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Norvium Bioscience | PREGABALIN | pregabalin | TABLET, EXTENDED RELEASE;ORAL | 211948-001 | Apr 13, 2021 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Adaptis | PREGABALIN | pregabalin | CAPSULE;ORAL | 216197-006 | Jul 18, 2022 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Strides Pharma | PREGABALIN | pregabalin | CAPSULE;ORAL | 209883-003 | Jan 24, 2024 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for pregabalin
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Upjohn | LYRICA | pregabalin | CAPSULE;ORAL | 021446-007 | Dec 30, 2004 | 5,563,175 | ⤷ Subscribe |
Upjohn | LYRICA | pregabalin | CAPSULE;ORAL | 021446-001 | Dec 30, 2004 | 5,563,175 | ⤷ Subscribe |
Upjohn | LYRICA | pregabalin | CAPSULE;ORAL | 021446-006 | Dec 30, 2004 | 5,563,175 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for pregabalin
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Zentiva k.s. | Pregabalin Zentiva k.s. | pregabalin | EMEA/H/C/004277 Neuropathic painPregabalin Zentiva k.s. is indicated for the treatment of peripheral and central neuropathic pain in adults.EpilepsyPregabalin Zentiva k.s. is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised anxiety disorderPregabalin Zentiva k.s. is indicated for the treatment of generalised anxiety disorder (GAD) in adults. |
Withdrawn | yes | no | no | 2017-02-27 | |
Zentiva, k.s. | Pregabalin Zentiva | pregabalin | EMEA/H/C/003900 Neuropathic pain, , , Pregabalin Zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults., , , Epilepsy, , , Pregabalin Zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation., , , Generalised anxiety disorder, , , Pregabalin Zentiva is indicated for the treatment of generalised anxiety disorder (GAD) in adults., , |
Authorised | yes | no | no | 2015-07-17 | |
Mylan S.A.S. | Pregabalin Mylan Pharma | pregabalin | EMEA/H/C/003962 EpilepsyPregabalin Mylan Pharma is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised Anxiety DisorderPregabalin Mylan Pharma is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults. |
Withdrawn | yes | no | no | 2015-06-25 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for pregabalin
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Peru | 20070693 | COMPOSICIONES FARMACEUTICAS SOLIDAS QUE CONTIENEN PREGABALINA | ⤷ Subscribe |
Uruguay | 29890 | COMPOSICIONES FARMACÉUTICAS SĂ“LIDAS QUE CONTIENEN PREGABALINA | ⤷ Subscribe |
Cyprus | 1115009 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for pregabalin
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0641330 | 27/2004 | Austria | ⤷ Subscribe | PRODUCT NAME: PREGABALIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/1/04/279/001 - EU/1/04/279/025 20040706 |
0934061 | PA2004017,C0934061 | Lithuania | ⤷ Subscribe | PRODUCT NAME: PREGABALINUM ((S)-3-(AMINOMETIL)-5-METILHEKSANO RUGSTIS); REGISTRATION NO/DATE: EU/1/04/279/001-025 20040725 |
0641330 | 2004C/022 | Belgium | ⤷ Subscribe | PRODUCT NAME: PREGABALIN; REGISTRATION NO/DATE: EU/1/04/279/001 20040708 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Pregabalin Market Analysis and Financial Projection Experimental
More… ↓